Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 782,012,736
  • Shares Outstanding, K 948,170
  • Annual Sales, $ 45,043 M
  • Annual Income, $ 10,590 M
  • EBIT $ 12,899 M
  • EBITDA $ 14,666 M
  • 60-Month Beta 0.34
  • Price/Sales 17.12
  • Price/Cash Flow 57.15
  • Price/Book 54.11

Options Overview Details

View History
  • Implied Volatility 31.20% ( +0.54%)
  • Historical Volatility 31.31%
  • IV Percentile 49%
  • IV Rank 26.80%
  • IV High 55.08% on 08/05/24
  • IV Low 22.46% on 06/28/24
  • Put/Call Vol Ratio 0.63
  • Today's Volume 14,071
  • Volume Avg (30-Day) 41,773
  • Put/Call OI Ratio 0.88
  • Today's Open Interest 275,364
  • Open Int (30-Day) 280,232

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 4.60
  • Number of Estimates 9
  • High Estimate 5.36
  • Low Estimate 4.20
  • Prior Year 2.58
  • Growth Rate Est. (year over year) +78.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
795.38 +3.41%
on 03/13/25
935.63 -12.09%
on 03/03/25
-34.69 (-4.05%)
since 02/18/25
3-Month
725.01 +13.45%
on 01/17/25
935.63 -12.09%
on 03/03/25
+57.80 (+7.56%)
since 12/18/24
52-Week
711.40 +15.62%
on 11/18/24
972.53 -15.43%
on 08/22/24
+59.85 (+7.85%)
since 03/18/24

Most Recent Stories

More News
Why Novo Nordisk Stock Outpaced the Market on Tuesday

Novo Nordisk (NYSE: NVO), the Danish company best known as the maker of weight loss drug Wegovy, expanded a little on the stock exchange Tuesday. The company was one of the rare enterprises seeing an increase...

NVO : 80.98 (+1.04%)
$SPX : 5,614.66 (-1.07%)
UBS : 33.85 (+1.29%)
LLY : 822.51 (-0.27%)
Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?

Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry.AMGN Stock PerformanceImage Source: Zacks Investment ResearchAmgen’s stock has been rising consistently,...

NVO : 80.98 (+1.04%)
LLY : 822.51 (-0.27%)
ABBV : 213.85 (-0.29%)
AMGN : 318.65 (+0.47%)
BMO Hosts Second Annual Obesity Summit on the Future of the GLP-1+ Market

/CNW/ - Join BMO and industry leaders in New York on March 25 for the BMO 2025 Obesity Summit to discuss the growing $150 billion obesity therapies market. The...

LLY : 822.51 (-0.27%)
Why Hims & Hers Stock Popped on Monday

Morgan Stanley had great news for Hims & Hers stock today, so why didn't it upgrade the stock?

AAPL : 212.69 (-0.61%)
HIMS : 31.49 (-9.22%)
NVO : 80.98 (+1.04%)
MS : 118.11 (+0.13%)
LLY : 822.51 (-0.27%)
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation

Are you reluctant to invest in stocks right now? That's understandable. Fear, uncertainty, and doubt have become the norm in early 2025 with rising stock market volatility .

NVO : 80.98 (+1.04%)
VRTX : 512.23 (-0.30%)
LLY : 822.51 (-0.27%)
3 Healthcare Stocks with Exciting Potential

3 Healthcare Stocks with Exciting Potential

OPCH : 34.33 (+1.30%)
LLY : 822.51 (-0.27%)
THC : 125.33 (-2.09%)
Generate Passive Income From This Low-Cost Vanguard ETF That Is Crushing the S&P 500 in 2025

Investors typically turn to dividend-paying stocks and exchange-traded funds (ETFs) to boost their passive income streams so that their returns aren't solely tied to stock price gains. But so far this...

GOOGL : 160.67 (-2.20%)
AAPL : 212.69 (-0.61%)
AVGO : 188.67 (-3.00%)
JPM : 234.97 (+0.44%)
JNJ : 164.25 (+0.87%)
BRK.TO : 39.23 (-0.08%)
UNH : 503.80 (+0.96%)
COMP : 8.82 (-2.00%)
MSFT : 383.52 (-1.33%)
TSLA : 225.31 (-5.34%)
V : 334.77 (+0.07%)
LLY : 822.51 (-0.27%)
Billionaire Ken Griffin More Than Doubled His Stake In This Market-Beating Growth Stock

"Billionaire" and "successful hedge fund manager" are titles that carry significant weight on Wall Street. These and others apply to Ken Griffin, CEO and founder of Citadel. It's no surprise that investors...

LLY : 822.51 (-0.27%)
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks

Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks

SUPN : 32.28 (+0.37%)
JNJ : 164.25 (+0.87%)
ZTS : 164.43 (-0.45%)
LLY : 822.51 (-0.27%)
PFE : 26.31 (+1.00%)
Is Amgen Stock a Buy, Sell, or Hold as Weight-Loss Drug Trials Kick Off?

Amgen is hoping to rival Novo Nordisk and Eli Lilly in the weight-loss drug market.

NVO : 80.98 (+1.04%)
LLY : 822.51 (-0.27%)
AMGN : 318.65 (+0.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 858.67
2nd Resistance Point 847.48
1st Resistance Point 834.99
Last Price 822.51
1st Support Level 811.32
2nd Support Level 800.13
3rd Support Level 787.65

See More

52-Week High 972.53
Fibonacci 61.8% 872.78
Fibonacci 50% 841.97
Last Price 822.51
Fibonacci 38.2% 811.15
52-Week Low 711.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar